TD Cowen Rates ICON Public (ICLR) buy, $197 Price Target

TD Cowen reaffirmed its positive stance on clinical research firm ICON Public Limited Company, pointing to steady demand for drug development services, a 15.98% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 11:01 AM EDT · Updated Jun 29, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen rated ICON Public Limited Company ($ICLR) "buy" with a $197 price target on June 25, 2026.

Since the rating, $ICLR is up 7.5% after 1 week, up 4.9% after 1 month and up 5.7% to date (from the $160.96 close on Jun 25, 2026).

ICLR ICON Public Limited Company

$170.18 -9.80% year to date

Daily close · Oct 16, 2026

Key Points

TD Cowen analyst Charles Rhyee reiterated a buy rating on ICON Public Limited Company on June 25, 2026, maintaining a price target of $197.00.
TD Cowen's $197 price target implies 15.98% upside from ICON Public Limited Company's ($ICLR) current $169.86 share price.
The stock traded around $169.86, sitting near its 50-day moving average of $167.30 and well above its 200-day moving average of $147.20.
Wall Street features 16 analyst opinions on the stock, reflecting a general buy outlook alongside additional updates from firms like Citigroup and Truist Securities.

Get $ICLR trade alerts by text

We text you when insiders, Congress or big funds trade $ICLR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICON Public Limited Company alert may contain errors. Disclosures

TD Cowen Maintains Buy Rating on ICON Public Limited Company

TD Cowen analyst Charles Rhyee reaffirmed a buy rating on ICON Public Limited Company (NASDAQGS: ICLR) on June 25, 2026, keeping the price target at $197.00. The decision highlights confidence in the company's operational position within the clinical research sector, where outsourced services for pharmaceutical and biotechnology clients continue to play a key role in bringing new treatments through clinical testing phases.

Analyst rating track record

TD Cowen vs. the S&P 500

YTD return -45.21% hypothetical

All-time return -12.59% S&P 500 +40.84%

vs. S&P 500 -53.43% behind the index

Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.

Stock Price Trades Near Moving Averages

Shares of ICON changed hands around $169.86 as the broader market assessed sector valuations. The equity has spent the past year trading in a 52-week range between a low of $66.57 and a high of $203.91. Current pricing places the stock right around its 50-day moving average of $167.30, while holding a comfortable distance above its longer-term 200-day moving average of $147.20.

12-month forecast

$ICLR price target

ICON Public Limited Company daily closes and this analyst's $197 target. Not advice.

Broader Wall Street Analyst Updates

Other financial institutions have also updated their outlooks for the company. On September 18, 2026, Citigroup maintained a neutral rating on the stock with a price target of $175.00, adjusting it from a prior target of $180.00. Earlier in the summer, on July 31, 2026, Citigroup maintained a neutral stance with an $180.00 target, while Truist Securities reiterated a buy rating with a $209.00 target. Mizuho also kept an outperform rating on June 26, 2026, with a target of $190.00, and Barclays maintained an equal-weight rating at a $175.00 target on June 25, 2026.

Clinical Research Operations in Dublin

Headquartered in Dublin, Ireland, ICON Public Limited Company operates as a global clinical research organization. The firm provides outsourced development, consulting, and commercialization services to pharmaceutical, biotechnology, and medical device companies. Its work covers everything from early phase compound selection and laboratory testing to large-scale Phase I-IV clinical trial management and post-market safety monitoring.

Looking Ahead to Upcoming Reports

Market participants tracking the stock will watch for the company's next earnings report, which is scheduled for release on October 21, 2026. That update will offer fresh visibility into quarterly revenue growth, operational margins, and overall demand for clinical trial services across global markets.